Filing Flows › Comparisons › KYMR vs IBRX
Kymera Therapeutics vs ImmunityBio: KYMR and IBRX compared
Kymera Therapeutics is the larger company: $65.0M of revenue in its latest quarter (Q2 2026) against $51.2M for ImmunityBio (Q2 2026). Kymera Therapeutics is growing faster (+466% against +94% a year earlier). Kymera Therapeutics is more profitable, with an operating margin of -116.3% against -120.4%.
Where the money goes: KYMR and IBRX
Kymera Therapeutics (KYMR) · Q2 2026
Kymera Therapeutics, Q2 2026: revenue $65.0M (+466% year over year), operating margin -116.3%, net loss $61.2M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.
ImmunityBio (IBRX) · Q2 2026
ImmunityBio, Q2 2026: revenue $51.2M (+94% year over year), operating margin -120.4%, net loss $230M, operating cash flow −$66.5M. The chart follows the revenue to costs, profit and cash.
| Kymera Therapeutics (KYMR) | ImmunityBio (IBRX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $65.0M | $51.2M |
| Revenue growth, Y/Y | +466% | +94% |
| Operating margin | -116.3% | -120.4% |
| Net earnings | −$61.2M | −$230M |
| Net margin | -94.2% | -449.6% |
| Operating cash flow | −$54.1M | −$66.5M |
Where the revenue comes from
ImmunityBio
- Product revenue, net: $50.7M (99%)
- Other revenues: $568K (1%)
Questions
Which is bigger, Kymera Therapeutics or ImmunityBio?
Kymera Therapeutics is the larger company: $65.0M of revenue in its latest quarter (Q2 2026) against $51.2M for ImmunityBio (Q2 2026).
Is Kymera Therapeutics or ImmunityBio growing faster?
Kymera Therapeutics is growing faster (+466% against +94% a year earlier).
Which is more profitable, Kymera Therapeutics or ImmunityBio?
Kymera Therapeutics is more profitable, with an operating margin of -116.3% against -120.4%.
More: Kymera Therapeutics earnings · how Kymera Therapeutics makes money · ImmunityBio earnings · how ImmunityBio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 5, 2026; 10-Q filed Aug 4, 2026). Fiscal quarters can end on different dates. Not investment advice.